Dengue and Zika are two mosquito-borne
diseases of great impact
on public health around the world in tropical and subtropical countries.
DENV and ZIKV belong to the Flaviviridae family and the Flavivirus genus. Currently, there are no effective therapeutic agents to treat
or prevent these pathologies. The main objective of this work was
to evaluate potential inhibitors from active compounds obtained from Marcetia taxifolia by performing inverse molecular
docking on ZIKV-NS3-helicase and ZIKV-NS5-RNA polymerase as targets.
This computational strategy is based on renormalizing the binding
scores of the compounds to these two proteins, allowing a direct comparison
of the results across the proteins. The crystallographic structures
of the ZIKV-NS3-helicase and ZIKV-NS5-RNA-polymerase proteins share
a great similarity with DENV homologous proteins. The P-loop active
site of the crystallographic structure of ZIKV-NS3-helicase presents
a high percentage of homology with the four dengue serotypes. It was
found that most ligands of the active compounds (5,3’-dihydroxy-3,6,7,8,4′-pentamethoxyflavone
(5DP); 5-hydroxy-3,6,7,8,3′,4′-hexamethoxyflavone (5HH);
myricetin-3-O-rhamnoside (M3OR)) from Marcetia taxifolia had a better affinity for ZIKV-NS3-helicase
than for ZIKV-NS5-RNA polymerase, as indicated by the negative multiple
active site correction (MASC) score, except for M3RG that showed a
higher affinity for ZIKV-NS5-RNA polymerase. On the other hand, the
AutoDock Vina scores showed that M3OR had the highest score value
(−9.60 kcal/mol) and the highest normalized score (1.13) against
ZIKV-NS3-helicase. These results in silico demonstrated that the nonstructural
proteins NS3-helicase and NS5-RNA polymerase, which share similar
molecular structures between the selected viruses, could become therapeutic
targets for some bioactive compounds derived from Marcetia
taxifolia.